Osteosarcoma is one of the most common bone tumors. However, the genetic basis for its pathogenesis remains elusive. Here, we investigated the roles of Hedgehog (Hh) signaling in osteosarcoma development. Genetically-engineered mice with ubiquitous upregulated Hh signaling specifically in mature osteoblasts develop focal bone overgrowth, which greatly resembles the early stage of osteosarcoma. However, these mice die within three months, which prohibits further analysis of tumor progression. We therefore generated a mouse model with partial upregulated Hh signaling in mature osteoblasts and crossed it into a p53 heterozygous background to potentiate tumor development. We found that these mutant mice developed malignant osteosarcoma with high penetrance. Isolated primary tumor cells were mainly osteoblastic and highly proliferative with many characteristics of human osteosarcomas. Allograft transplantation into immunocompromised mice displayed high tumorigenic potential. More importantly, both human and mouse tumor tissues express high level of yes-associated protein 1 (Yap1), a potent oncogene that is amplified in various cancers. We show that inhibition of Hh signaling reduces Yap1 expression and knockdown of Yap1 significantly inhibits tumor progression. Moreover, long non-coding RNA H19 is aberrantly expressed and induced by upregulated Hh signaling and Yap1 overexpression. Our results demonstrate that aberrant Hh signaling in mature osteoblasts is responsible for the pathogenesis of osteoblastic osteosarcoma through Yap1 and H19 overexpression.
INTRODUCTION
Osteosarcoma is one of the most common malignant bone tumors in children and adolescents. 1, 2 The five-year survival rate for osteosarcoma patients is around 70%, but for patients with recurrent disease or metastasis at diagnosis this drops significantly to only 20-30%. To date, genetic contributions to the pathogenesis of osteosarcoma remain unclear and the molecular bases for the development of different osteosarcoma subtypes remain elusive. Previous genetic mouse models of osteosarcoma are mostly fibroblastic or undifferentiated in nature [3] [4] [5] but the osteoblastic form is lacking. A recent report indicates that conditional knockout of the p53 allele versus knockdown of p53 using shRNA approach resulted in different subtypes of osteosarcoma. 6 This raises the importance of the signaling intensity and timing of genetic manipulation at various stages within the osteoblastic lineage that contributes to different subtypes of the bone tumor. More research in this area will advance further development of better therapeutic interventions for precise treatment of each osteosarcoma subtype.
Hedgehog (Hh) signaling has been widely implicated in the development of multiple cancers in which many of them can be largely phenocopied by mutant mouse models. [7] [8] [9] [10] [11] [12] For instance, aberrant activation of Hh signaling is implicated in human medulloblastoma. It has been shown that transcriptional cofactor yes-associated protein 1 (Yap1), a downstream effector of tumor suppressive Hippo pathway, is responsible for a subset of Hhassociated medulloblastoma. 13 In addition, YAP1 overexpression is frequently found in different human cancers and many of them are related to a dysregulated Hippo signaling pathway. [14] [15] [16] [17] [18] In the context of osteoblast lineage, Yap1 interacts with Runx2, an important transcription factor for osteoblast commitment, to regulate Osteocalcin expression. 19, 20 However, whether Hh signaling and Hippo signaling are implicated in the pathogenesis of osteosarcoma remained elusive. Previous studies showed that Hh signaling may be correlated with osteosarcoma. 21, 22 Inhibition of Hh signaling or GLI2 knockdown in human osteosarcoma cell lines reduces cell proliferation and enhances apoptosis. However, these results are mainly based on in vitro analyses and expression association studies in patient specimens without detailed investigation of the molecular mechanisms.
Long non-coding RNAs (lncRNAs) play a key regulatory role in the development of various tumors. Aberrant expression of certain lncRNAs causes them to function as oncogenes, and they are associated with tumor growth and invasion. [23] [24] [25] [26] [27] Among these, H19 is one of the most extensively studied candidates. H19 is an imprinted gene expressed from the maternal allele during embryonic development and repressed after birth. 28 Loss of imprinting of H19 in CpG methylation of CCCTC-binding factor (CTCF)-binding site is associated with osteosarcoma. 29 However, the molecular mechanism in regulating H19 expression remains unclear.
Here, we have addressed the importance of Hh signaling in the onset of osteoblastic osteosarcoma using geneticallyengineered mouse models. We generated an osteoblastic osteosarcoma mouse model and found that upregulated Hh signaling induces osteosarcoma through Yap1 and H19 overexpression. In addition, Yap1 is found to be highly expressed in both human and mouse osteosarcomas. Our data indicate that aberrant Hh signaling in mature osteoblasts leads to the development of osteoblastic osteosarcoma.
RESULTS

Upregulated Hh signaling induces osteoblastic osteosarcoma
We previously generated the Ptch1 c/c ;HOC-Cre mutant mice in which Hh signaling is upregulated specifically in mature osteoblasts. 30 Interestingly, apart from the bone remodeling defects, focal bone overgrowth was frequently observed in long bones of the Ptch1 c/c ; HOC-Cre mutant mice (Supplementary Figure S1a-c) . Serum alkaline phosphatase level was significantly increased. 30 These observations are very similar to the early stage of osteosarcoma development and suggest a role of Hh signaling in the pathogenesis of this disease. Unfortunately, the mutant mice died within three months due to unknown reasons, which prohibited a detailed investigation of tumor progression. In order to further examine the functional roles of Hh signaling in osteosarcoma development, we partially upregulated Hh signaling by using a heterozygous mutant, Ptch1 c/ þ ;HOC-Cre, in which only one copy of the Ptch1 allele is removed in mature osteoblasts. The survival rate of the heterozygous mice was comparable to that of the wild-type mice without any bone tumor formation within the 16 months observation (Figure 1a) . In order to enhance the frequency of osteosarcoma occurrence, we crossed the Ptch1 c/ þ ;HOC-Cre mutant mice to a p53 À / À mutant mice to generate Ptch1 c/ þ ;p53 þ / À ; HOC-Cre mutant mice. p53 À / À mutant mice have been shown to develop multiple cancers including osteosarcoma, but the occurrence of osteosarcoma is very low by itself 31 because the effect is masked by the early onset of other cancers. The Ptch1 c/ þ ; p53 þ / À ;HOC-Cre mutant mouse is viable, fertile and developmentally normal as compared to age-matched wild-type mice. Interestingly, these mice started to develop observable bone tumors as early as 7 months old, and the incidence significantly increased at 11 months onwards with about 70% penetrance ( Figure 1a ). These tumors were located mostly in the forelimbs and hind limbs (Figures 1b and d) , which are the most common primary sites in human osteosarcoma. More interestingly, bone tumors were also frequently found in the spine (Supplementary Figure S1d) , which led to lower body paralysis of the mutant mice. Bone tumors in other locations such as ribs and skull were less frequently found (Supplementary Figure S1e and f) . Occasionally, pulmonary metastasis was noted in the lungs with tumor nodule formation (Supplementary Figure S1g) . X-ray analysis revealed that the primary tumors were composed of highly mineralized tissues regardless of the site of occurrence (Figure 1c ). Histological sections confirmed that the tumors were composed of abundant osteoids with multinucleated cells (Figure 1e ). All these phenotypes greatly resemble the characteristics of human osteoblastic osteosarcoma. Molecular analysis showed that Hh targets Gli1, Gli2 and Hhip1 were all highly upregulated in the tumor tissues (Figure 1f ). Osteoblast markers Runx2, Osteocalcin (Oc) and Osteopontin (Opn) were significantly increased ( Figure 1g ). These data suggest that the origins of the tumors were derived from osteoblasts with upregulated Hh signaling. In addition, the majority of the Ptch1 c/ þ ;p53
;HOC-Cre mutant mice developed only bone tumors, and not tumors in other organs within the observation period. Only a few p53 þ / À mutant mice (n ¼ 3) showed spontaneous tumor development in other organs, which is not relevant to this study ( Figure 1a) . Altogether, these data suggest that aberrant Hh signaling in mature osteoblasts induces osteoblastic osteosarcoma. þ / À ;HOC-Cre for Hh target genes and specific bone markers, respectively (n ¼ 3). Statistical analyses are presented by student t-test as shown (***Po0.01).
Primary tumor cells possess cancer characteristics both in vitro and in vivo
In order to further analyze the cancer properties of the tumors from the Ptch1 c/ þ ;p53 þ / À ;HOC-Cre mutant mice, we isolated primary cells from the tumors and cultured them for cellular and molecular analysis. First, we tested the origin of the tumor cells by making use of the LacZ knockin allele derived from the floxed allele of Ptch1 in which Cre-mediated recombination induces LacZ expression. 32 We assessed the primary tumor cells named Kios-5 in culture by X-gal staining. As expected, strong expression was detected from the isolated cells (Supplementary Figure S2a) . They also expressed high levels of osteoblast markers as well as cancer marker genes such as c-Fos, Ezrin, Survivin and cIAP when compared with wild-type calvarial osteoblasts (Figure 2a ). We isolated primary cells from at least seven individual tumors (Kios5-9S1) from different Ptch1 c/ þ ;p53 þ / À ;HOC-Cre mutant mice, and they all showed consistent results. These findings suggest that the isolated primary cells were osteosarcoma cancer-like cells.
Since many of the cancer cells are highly proliferative, we tested the proliferation of the primary cells by examining the expression of phospho-histone H3 (PH3). In the Kios primary tumor cells, there were more PH3-positive cells as compared to that of wild-type calvarial osteoblasts or MC3T3-E1 cells, respectively (Figures 2b and c and Supplementary Figure S2b and c). In addition, MTT assay also revealed a significant increase in cell proliferation rate (Supplementary Figure S2d) . When the osteoblasts were cultured in osteogenic condition, Kios cells showed a significant increase of mineralized bone nodules with Alizarin Red and von Kossa staining when compared with control osteoblasts (Figure 2d and Supplementary Figure S2e ). These data suggest that osteoblast differentiation and maturation in the primary Kios cells were highly accelerated.
Other typical features of tumorigenicity are enhanced cell migration and invasion. Therefore, we examined the primary tumor cells with wound healing and trans-well invasion assay respectively. As expected, Kios cells showed a significant increase in cell migration and invasion as compared to that of the controls (Figures 2e and f and Supplementary Figure S2f) . Furthermore, soft agar assay showed that Kios cells were able to form colonies, confirming their capability of anchorage-independent growth (Supplementary Figure S2g) . These findings strongly indicate that the primary cells undergo malignant transformation that resembles features of cancer cells. Next, we tested the tumorigenicity of the primary cells in vivo by injecting primary tumor cells into nude mice (Figure 3 ). Both subcutaneous injection and intra-tibial injection formed bone tumors with over 80% incidence rate (Figures 3a and e) . These data indicate that primary cells isolated from the tumors are highly tumorigenic and possess characteristics very similar to human osteosarcoma.
Hh signaling induces Yap1 overexpression for osteosarcoma development To test whether malignant transformation was caused by aberrant Hh signaling, we tested the expression of Hh target genes in the primary Kios cells. Both Gli1 and Gli2 were highly upregulated in the Kios cells as compared to the controls (Figure 4a and Supplementary Figure S3a-b) . Next, we treated the primary tumor cells with Hh-specific inhibitor GDC-0449. In the Kios cells, both Gli1 and Gli2 expression were significantly reduced with GDC-0449 treatment (Figures 4a and Supplementary Figure S3c and d) . To further understand the molecular mechanism underlying osteosarcoma development, we searched signaling pathways that have been widely implicated in cancer development. We found that Hippo signaling effector Yap1 was highly expressed in the tumor tissues isolated from our Figure S4d) , respectively. Using a TEAD/Sd luciferase reporter, 33 we found that the transcriptional activity of Yap1 was increased in the Kios-5 primary cells, and its activity was inhibited by GDC-0449 treatment (Figure 4e) . Furthermore, Amphiregulin, a recently identified downstream target of Hippo signaling 34 was also upregulated in both tumor tissues and primary cancer cells (Supplementary Figure S4e and f) . Altogether, these data indicate that Hippo signaling is regulated by Hh signaling during osteosarcoma development. We also isolated primary osteoblasts directly from the calvaria of the neonatal Ptch1 c/c ; HOC-Cre mutant mice and found that Hippo effectors and target genes were highly upregulated (Supplementary Figure S4g and h) . These data indicate that Hh signaling regulates the Hippo pathway independent of p53 signaling in our mouse models. (Figures 5a and b) . More importantly, when these transduced cells were injected into nude 
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Yap1 expression attenuates tumor formation To test whether Yap1 overexpression led to osteosarcoma tumor formation, we knocked down Yap1 expression in the primary tumor cells by ShYAP approach. To avoid non-specific binding effects, two independent ShYAP lentiviruses were tested and both of them reduced the proliferation of the primary tumor cells as shown by reduced PH3 expression
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Kios-1 . These data indicate that Yap1 contributes to the aberrant Hh signaling in promoting tumor progression. Next, we tested if Yap1 overexpression is also implicated in human osteosarcoma. We examined the expression level of Yap1 in a human osteosarcoma tissue array and 78% of the patient specimens tested showed moderate to high levels of Yap1 expression (Figure 5f and Supplementary Table S1 ). When we compared the Yap1 expression level with the patient survival data (Supplementary Table S2 ), no significant correlation was observed. However, it is noted that higher number of osteosarcoma tissues with fibroblastic or chondroblastic origins showed either no or lower level of Yap1 expression. In addition, we also evaluated the correlation of Hh pathway activation and Yap1 expression in human osteosarcoma patient samples by using expression dataset from Jones et al.
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( Figure 5g ). The expression of GLI1, GLI2 and Yap1 were all significantly upregulated in the osteosarcoma patient samples as compared to that of the normal samples. Altogether, these data suggest that Hippo signaling has an important role in the pathogenesis and progression of human osteosarcoma.
H19 is induced by Yap1 overexpression To further identify the underlying molecular mechanism, we activated Yap1 by genetic removal of mammalian Hippo core components Mst1 and Mst2 simultaneously in embryonic stem cells and analyzed the gene expression profile changes by microarray analysis (Supplementary Figure S6) . Our data showed that among many different genes that were highly upregulated by Yap1 activation, lncRNA H19 was one of the candidates with the highest relevance in cancer development (Supplementary Figure S6) . We next tested H19 expression in the mouse osteosarcoma tissues and primary osteosarcoma cells. Consistent to the microarray analysis, H19 was highly upregulated in the tumor tissues and the primary Kios cells, respectively (Figures 6a and b) . 35 Fourteen osteosarcoma patient samples were compared with four normal controls. Red arrows represent higher expression and blue arrows represent lower expression. Statistical analyses are presented by student t-test as shown (***Po0.01; **Po0.05).
In addition, ShYap knockdown in the Kios cells successfully inhibited the expression of H19 suggesting that Yap1 regulates the expression of H19 in ostesosarcoma (Figure 6c) . Similarly, treatment with Hh inhibitor in primary tumor cells also inhibited H19 expression (Figure 6d ). In contrast, forced expression of Yap1 into osteoblasts induced H19 expression, along with the activation of Hippo target genes (Figure 6e ). Treatment with Shh or Hh agonist purmorphamine induced a subtle but significant H19 expression in wild-type primary osteoblasts as well (Figure 6f) . Altogether, our data indicate that aberrant Hh signaling leads to overexpression of both Yap1 and H19, and that this is responsible for the pathogenesis and malignant transformation of osteoblastic osteosarcoma.
DISCUSSION
Here we show that upregulated Hh signaling in mature osteoblasts significantly induces osteoblastic osteosarcoma and that Yap1 and H19 are overexpressed and function downstream of Hh signaling as one of the underlying molecular mechanisms that leads to bone tumor formation. Furthermore, YAP1 overexpression is also observed in human patient specimens, suggesting that inhibition of Hh signaling and YAP1 expression are of significant therapeutic value.
The initial bone overgrowth phenotypes observed in the homozygous Ptch1 c/c ; HOC-Cre mutant mice led us to hypothesize that Hh signaling is implicated in osteosarcoma development. Focal bone overgrowth tissues were observed in young mice (Supplementary Figure S1a-c) , which is highly relevant to osteosarcoma in humans where the majority of patients are adolescents and youngsters. 2 However, the mutant mice die within 3 months of birth, which makes it difficult to carry out detailed analysis of bone tumorigenesis. To circumvent this problem, we generated the Ptch1 c/ þ ; p53 þ / À ;HOC-Cre mutant mice in which Hh signaling is partially upregulated in a p53 heterozygous background because previous studies showed that removal of p53 potentiates the onset of osteosarcoma in other mouse models such as retinoblastoma (Rb) mutant mice. 3, 4 Here, we used only p53 þ / À mice for our analysis because p53
À / À mutant mice show a high frequency of spontaneous tumor development in other organs, which masks the specific effect of Hh signaling in bone tumor development. In our model, even with the heterozygous background of p53, accelerated onset of osteosarcoma development is observed. Some of the mutant mice also showed pulmonary metastasis at a late stage, which suggests that our mouse model is highly relevant to human osteosarcoma. In addition, tumor cells isolated from our mutant mice showed strong LacZ expression (Supplementary Figure S2a) , further confirming that the tumors were derived from upregulated Hh signaling. We also analyzed osteoblasts isolated from the Ptch1 c/c ;HOC-Cre mutant mice alone, and we also found that Yap1 expression as well as Hippo downstream target genes were all highly upregulated without the influence from the manipulation of the p53 allele (Supplementary Figures S4e, g and h) . Collectively, our data indicate that the initiation of osteosarcoma in our mouse model is mainly caused by upregulated Hh signaling.
Another characteristic of our mouse model is that most of the developed bone tumors are mainly osteoblastic with massive osteoid formation, which is different from the preosteoblastrestricted deletion of p53 or Rb, where tumors are mainly fibroblastic or of undifferentiated form. 3, 4 This clearly demonstrates the specific roles of Hh signaling in osteoblastic osteosarcoma development in which genetic manipulation in more mature osteoblasts (osteocalcin þ cells) instead of premature osteoblasts (osterix þ cells) or mesencymal stem cells (prx1 þ cells) may give rise to different subtypes of osteosarcoma. Although it is proposed that the origin of osteosarcoma is mainly derived from more primitive progenitor cells, [36] [37] [38] a recent study using a transgenic mice that expressed the SV40 T antigen by osteocalcin promoter also presented solid osteosarcoma tumors with significant calcification. 39 Further analysis revealed a deletion in Prkar1a that led to deregulated PKA signaling and Rankl overexpression. Indeed, we previously showed that Ptch1 c/c ;HOC-Cre mutant mice also display significant induction of Rankl expression. 30 Many of the phenotypes from their transgenic mice were highly similar to our osteosarcoma mouse models in this study. Their findings together with ours indicate that osteoblastic osteosarcoma is originated from more mature osteoblasts.
Previous studies showed that GLI2 is highly expressed in human osteosarcoma samples 21, 22 and treatment with Hh-specific inhibitor cyclopamine in human osteosarcoma cell lines inhibited cell proliferation. 40 These findings hinted at the importance of aberrant Hh signaling in human osteosarcoma development. However, no genetically engineered animal model with detailed molecular mechanism is available. Here, we genetically demonstrated that Hh signaling induces osteosarcoma development through Yap1 and H19 overexpression. Our studies revealed that the Hippo pathway is a potential target for the treatment of osteosarcoma. Previous studies showed that 65% of neurofibromatosis 2 heterozygous mice developed osteosarcomalike disease 41 and it has been suggested that neurofibromatosis 2/Merlin is one of the regulators acting upstream of Yap1. 42 These findings are in agreement with our results suggesting that Hh signaling interacts with Hippo signaling for osteosarcoma development. In addition, a recent study showed that Amphiregulin, a secretory factor is also a downstream target of Hippo signaling in MCF10A breast cancer cells. 34 Our data also confirmed that Amphiregulin is highly upregulated in both tumor tissues and primary osteosarcoma cells from our model (Supplementary Figure S4e and f) . Altogether, our data support the notion that Hh signaling interacts with Hippo signaling for the pathogenesis of osteosarcoma.
Although our study strongly suggests that Hh-induced Yap1 overexpression is associated with dysregulated Hippo signaling, it should be noted that Yap1 expression can be also regulated by other signaling pathways. It has been previously reported that Yap1 is a mediator of Src/Yes signaling and it functions to inhibit Runx2 activity during osteoblast differentiation. 20 However, our study showed that Yap1 overexpression indeed promotes both Runx2 and Osteocalcin expression in our mouse model. These observations revealed the complexity of the regulation of Yap1 activity as well as its interaction with other key factors by different pathways. Runx2 is a key transcription factor for osteoblast differentiation, and it modulates the expression of cell cycle regulators in osteoblasts. 43 The proliferation of Runx2
osteoblasts is much faster than that of the wild-type osteoblasts, suggesting that Runx2 has an antiproliferative function. 44 However, enhanced expression of Runx2 is observed in many human osteosarcoma patient samples as well as human osteosarcoma cell lines, [45] [46] [47] indicating that Runx2 may have an oncogenic function in tumor etiology. Other studies also showed that RUNX2 controls the expression of matrix metalloproteinases and VEGF that may be related to the process of cancer metastasis. 48, 49 A more detail investigation of the effect of other Hippo core components such as Mst1/2 on Runx2 activity may help to address this question.
Our results demonstrate that H19 overexpression may contribute to the malignant transformation of osteosarcoma. H19 expression has been previously implicated in human osteosarcoma. 29, 50 Mutually exclusive loss of imprinting of H19 and IGF2 leads to reciprocal biallelic gene expression of each other and provides augmented growth-promoting signals to tumor growth. The regulation of H19 expression was shown to be regulated by epigenetics through methylation of the imprinting control region. The molecular regulation of H19 in tumorigenesis is still controversial, and its functional roles warrant further investigation. However, there is substantial evidence that H19 may function as an oncogene for the development of various cancers such as choriocarcinoma, hepatocellular carcinomas, esophageal cancer and ovarian cancers. [51] [52] [53] [54] Our studies provide the first evidence that H19 could be regulated by Hh signaling and Yap1 expression, and it may explain at least in part the pathogenesis of a subset of osteosarcomas. Quantitative RT-PCR Total RNA was isolated using the TRIzol reagent (Life Technologies) according to the manufacturer's instructions. Relative mRNA levels were examined using a Platinum SYBR Green kit (Life Technologies). Samples were normalized with b-tubulin or Gapdh expression.
MATERIALS AND METHODS
Migration assay and transwell invasion assay
Cells were pretreated with mitomycin C (4 mg/ml, Sigma-Aldrich) for 2 h prior to analysis. Cell migration was monitored for 12 h to 16 h by introduction of a scratch in confluent cells. For trans well invasion assay, BD Falcon Cell culture inserts were coated with BD Matrigel matrix (BD Bioscience, San Jose, CA, USA). Cells were seeded into each invasion chamber and incubated for 48 h. Non-invading cells were removed by cotton swabs and cells at the lower surface of the membrane were stained with crystal violet (Sigma-Aldrich).
Lentiviral transduction and luciferase assay
ShYAP#3 and ShYAP#4 targeting different cDNA regions of Yap1 were constructed. Lentiviruses were prepared according to standard procedures. ShLuc or ShScramble were used as controls for comparison. Cells were incubated with individual lentivirus for 24 h and subsequent selection was performed with puromycin treatment for 4 days. Over 80% transduction efficiency was achieved. For luciferase assay, luciferase activity was measured 48 h after transfection according to the Dual-luciferase Reporter Assay System (Promega, Madison, WI, USA). The results are presented as the average±s.d. from three independent transfections.
Subcutaneous and intra-tibial injection 2 Â 10 6 cells were mixed with 10% BD Matrigel in saline and injected subcutaneously to the rear flank of 6-8 weeks-old nude mouse using 27G needle (n ¼ 14). For intra-tibial injection, 5 Â 10 5 cells were used and injected directly to the cavity of the proximal tibia from the knee joint of the hind limbs (n ¼ 18). Tumor growth was monitored for 1.5 months.
Tissue array Paraffin-embedded tissue array (SuperBioChips Lab, Seoul, Korea) with 54 human osteosarcoma patient samples from both sexes were examined for Yap1 expression by immunohistochemistry. Five normal bone tissues were included as controls. Standard procedures for immunohistochemistry were followed.
